Supraventricular Tachycardia (SVT)
Conditions
Keywords
diltiazem, adenosine, emergency medicine
Brief summary
This is a small, pilot study with a primary goal of assessing patient perceptions of two medication treatments for supraventricular tachycardia in adult patients treated in the Emergency Department.
Interventions
DRUGadenosine
IV adenosine at standard doses for SVT (6 mg, 12 mg)
DRUGdiltiazem
IV diltiazem at standard doses for SVT (0.25 mg/kg)
Sponsors
Anne E. Zepeski
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
1. Adult patients (18 years and older) 2. Diagnosis of acute, stable SVT in the emergency department
Exclusion criteria
1. Receipt of IV AV-nodal blocking agents prior to study enrollment (includes adenosine, non-dihydropyridine calcium channel blockers, beta-antagonists in pre-hospital and/or hospital setting). 2. Reported or confirmed personal history of Wolff-Parkinson-White (WPW) syndrome 3. History of heart failure with reduce ejection fraction (HFrEF) (LVEF\</= 40%) 4. Severe bronchoconstrictive lung disease 5. Prior hypersensitivity to study medication 6. Previously enrolled in pilot study 7. Pregnant 8. Incarcerated
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Feasibility outcome | From enrollment to the end of ED encounter (up to 24 hours). | Patients with stable SVT are identified in the ED (Threshold \>90%) |
Countries
United States
Contacts
CONTACTAnne Zepeski, PharmD
PRINCIPAL_INVESTIGATORAnne Zepeski, PharmD
University of Iowa
Outcome results
None listed